Davenport & CO LLC Phathom Pharmaceuticals, Inc. Transaction History
Davenport & CO LLC
- $16.8 Billion
- Q3 2024
A detailed history of Davenport & CO LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Davenport & CO LLC holds 10,000 shares of PHAT stock, worth $185,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$185,000
Previous $103,000
74.76%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
126Shares Held
59.6MCall Options Held
467KPut Options Held
34.9K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$187 Million6.14% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$138 Million28.04% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$64.7 Million4.3% of portfolio
-
Invesco Ltd. Atlanta, GA3.14MShares$58.2 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$54.1 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $725M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...